SOURCE-LINKED STUDY SUMMARY
Tirzepatide Once Weekly for the Treatment of Obesity.
Abstract summarizedQuality not appraised
- What was studied
- Phase 3 randomized trial comparing three studied tirzepatide doses with placebo for weight loss.
- Who / model studied
- 2539 adults with obesity, or overweight with a weight-related complication, without diabetes; treatment lasted 72 weeks.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Both main weight outcomes favored tirzepatide. Across increasing studied doses, average weight fell 15.0%, 19.5% and 20.9%, versus 3.1% with placebo. At least 5% weight loss occurred in 85%, 89% and 91%, versus 35%. Digestive symptoms were common; adverse events caused treatment withdrawal in 4.3%, 7.1% and 6.2%, versus 2.6%.
- Limitations & context
- Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa2206038